The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- NPC News
- Pandemic Response
- Patient Centered Formulary & Benefit Design
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Showing 97 Results
NPC Shares Input on CMS’ Data Collection Requirements
NPC comments offer input on CMS' approach to data collection that would inform the agency's implementation of provisions within the Inflation Reduction Act that enable government price-setting for…
NPC Comments on CMS Information Collection Request for Negotiation Data Elements
NPC's comments offer input on the agency's latest efforts to implement the drug price-setting provisions of the Inflation Reduction Act through the design of a data collection process.
NPC Comments on CMS Medicare Drug Price Negotiation Program
NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less…
The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Day serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies do…
After 30 years of 340B, it's time for data and an honest conversation
In a commentary published in STAT, NPC's John M. O’Brien outlines why transparency is essential to assessing the true impact of 340B.
Good Health Policy Requires High-Quality Evidence
In health policy debates, honest, realistic and evidence-based discussions are foundational.
Characterizing Health Plan Evidence Review Practices
The study finds that some plans updated the evidence in their coverage policies for specialty medicines more often than others, and the type of evidence plans cited in their coverage policies…
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
An Oversimplified Drug Price Policy That Misses the Point
Drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
The Impact of Price Regulation on Innovation: What the Research Shows
Potential drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access
On a recent episode of VITAL HEALTH podcast, John M. O’Brien discusses the health care ecosystem and the importance of fostering biopharmaceutical innovation and improving patient access.
Health Care Spending Effectiveness: Estimates Suggest that Spending Improved U.S. Health from 1996 to 2016
This research assessed the effectiveness of U.S. health care spending by comparing changes in health outcomes and found that, overall, innovations in health care are creating more cost-effective care…
Health Care Spending Guiding Principles
NPC established a set of principles to assess health care spending estimates and policies to ensure alignment with the goals of patient-centered care.
Innovation Matters: Changing Lives for Cystic Fibrosis Patients
In this video from NPC’s Innovation Matters series, cystic fibrosis patient advocate Katherine Fielding discusses how the invention of modulator therapies has changed her life and how more innovation…
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Innovation Matters: Revolutionary Changes for Arthritis Patients
Anna Hyde, vice president of advocacy and access for the Arthritis Foundation, discusses how biopharmaceutical innovation has advanced the health of people living with arthritis.
Innovation Matters: The Evolution of Cancer Therapies
In this video from NPC’s Innovation Matters series, Dr. Peter Emtage describes the evolution of cancer therapies and the importance of ensuring patient access to these medicines.
Innovation Matters: The Unintended Consequences of Drug Pricing Regulation
In NPC’s Innovation Matters video series, hear from patient advocates, researchers, and other stakeholders about the potential unintended consequences for patient health if drug pricing policies harm…